DOXIMITY INC-CLASS A (DOCS) Stock Fundamental Analysis
USA - New York Stock Exchange - NYSE:DOCS - US26622P1075 - Common Stock
43.65 USD
+0.16 (+0.37%)
43.68 USD
+0.03 (+0.07%)
We assign a fundamental rating of 7 out of 10 to DOCS. DOCS was compared to 35 industry peers in the Health Care Technology industry. DOCS scores excellent points on both the profitability and health parts. This is a solid base for a good stock. DOCS is not priced too expensively while it is growing strongly. Keep and eye on this one! With these ratings, DOCS could be worth investigating further for growth and quality investing!.
1. Profitability
1.1 Basic Checks
In the past year DOCS was profitable.
In the past year DOCS had a positive cash flow from operations.
Each year in the past 5 years DOCS has been profitable.
In the past 5 years DOCS always reported a positive cash flow from operatings.
1.2 Ratios
The Return On Assets of DOCS (20.13%) is better than 100.00% of its industry peers.
DOCS has a better Return On Equity (23.10%) than 100.00% of its industry peers.
The Return On Invested Capital of DOCS (18.16%) is better than 100.00% of its industry peers.
DOCS had an Average Return On Invested Capital over the past 3 years of 14.17%. This is significantly above the industry average of 6.61%.
The 3 year average ROIC (14.17%) for DOCS is below the current ROIC(18.16%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 20.13% | ||
| ROE | 23.1% | ||
| ROIC | 18.16% |
ROA(3y)13.75%
ROA(5y)12.65%
ROE(3y)16.22%
ROE(5y)15.68%
ROIC(3y)14.17%
ROIC(5y)16.48%
1.3 Margins
With an excellent Profit Margin value of 40.72%, DOCS belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
In the last couple of years the Profit Margin of DOCS has grown nicely.
The Operating Margin of DOCS (39.72%) is better than 100.00% of its industry peers.
DOCS's Operating Margin has improved in the last couple of years.
DOCS has a better Gross Margin (90.20%) than 97.14% of its industry peers.
In the last couple of years the Gross Margin of DOCS has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 39.72% | ||
| PM (TTM) | 40.72% | ||
| GM | 90.2% |
OM growth 3Y6.88%
OM growth 5Y16.16%
PM growth 3Y0.28%
PM growth 5Y33.35%
GM growth 3Y0.66%
GM growth 5Y0.68%
2. Health
2.1 Basic Checks
DOCS has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
Compared to 1 year ago, DOCS has more shares outstanding
The number of shares outstanding for DOCS has been increased compared to 5 years ago.
DOCS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
An Altman-Z score of 32.63 indicates that DOCS is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 32.63, DOCS belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
There is no outstanding debt for DOCS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 32.63 |
ROIC/WACC1.94
WACC9.37%
2.3 Liquidity
DOCS has a Current Ratio of 7.79. This indicates that DOCS is financially healthy and has no problem in meeting its short term obligations.
DOCS has a better Current ratio (7.79) than 91.43% of its industry peers.
A Quick Ratio of 7.79 indicates that DOCS has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 7.79, DOCS belongs to the best of the industry, outperforming 91.43% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.79 | ||
| Quick Ratio | 7.79 |
3. Growth
3.1 Past
DOCS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 46.43%, which is quite impressive.
DOCS shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 79.21% yearly.
The Revenue has grown by 20.21% in the past year. This is a very strong growth!
DOCS shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 37.42% yearly.
EPS 1Y (TTM)46.43%
EPS 3Y20.79%
EPS 5Y79.21%
EPS Q2Q%50%
Revenue 1Y (TTM)20.21%
Revenue growth 3Y18.42%
Revenue growth 5Y37.42%
Sales Q2Q%23.16%
3.2 Future
DOCS is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.75% yearly.
The Revenue is expected to grow by 11.49% on average over the next years. This is quite good.
EPS Next Y14.02%
EPS Next 2Y11.19%
EPS Next 3Y11.61%
EPS Next 5Y14.75%
Revenue Next Year13.88%
Revenue Next 2Y12.44%
Revenue Next 3Y11.89%
Revenue Next 5Y11.49%
3.3 Evolution
The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 26.62, which means the current valuation is very expensive for DOCS.
DOCS's Price/Earnings ratio is a bit cheaper when compared to the industry. DOCS is cheaper than 80.00% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 26.38. DOCS is around the same levels.
DOCS is valuated quite expensively with a Price/Forward Earnings ratio of 25.04.
Compared to the rest of the industry, the Price/Forward Earnings ratio of DOCS indicates a somewhat cheap valuation: DOCS is cheaper than 71.43% of the companies listed in the same industry.
DOCS's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 23.83.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 26.62 | ||
| Fwd PE | 25.04 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of DOCS indicates a somewhat cheap valuation: DOCS is cheaper than 62.86% of the companies listed in the same industry.
71.43% of the companies in the same industry are more expensive than DOCS, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 26.33 | ||
| EV/EBITDA | 25.53 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates DOCS does not grow enough to justify the current Price/Earnings ratio.
DOCS has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)1.9
PEG (5Y)0.34
EPS Next 2Y11.19%
EPS Next 3Y11.61%
5. Dividend
5.1 Amount
DOCS does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
43.65
+0.16 (+0.37%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)
Earnings (Next)
Inst Owners91.34%
Inst Owner Change0.15%
Ins Owners1.96%
Ins Owner Change0.19%
Market Cap8.22B
Revenue(TTM)621.33M
Net Income(TTM)253.03M
Analysts77.04
Price Target69.79 (59.89%)
Short Float %4.14%
Short Ratio2.61
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)16.98%
Min EPS beat(2)16.41%
Max EPS beat(2)17.55%
EPS beat(4)4
Avg EPS beat(4)25.31%
Min EPS beat(4)16.41%
Max EPS beat(4)36.67%
EPS beat(8)8
Avg EPS beat(8)23.42%
EPS beat(12)12
Avg EPS beat(12)22.47%
EPS beat(16)16
Avg EPS beat(16)28.98%
Revenue beat(2)2
Avg Revenue beat(2)3.67%
Min Revenue beat(2)2.52%
Max Revenue beat(2)4.82%
Revenue beat(4)4
Avg Revenue beat(4)4.22%
Min Revenue beat(4)1.38%
Max Revenue beat(4)8.16%
Revenue beat(8)7
Avg Revenue beat(8)3.68%
Revenue beat(12)9
Avg Revenue beat(12)2.53%
Revenue beat(16)12
Avg Revenue beat(16)2.69%
PT rev (1m)-4.38%
PT rev (3m)-1%
EPS NQ rev (1m)-0.69%
EPS NQ rev (3m)0.14%
EPS NY rev (1m)3.68%
EPS NY rev (3m)3.73%
Revenue NQ rev (1m)0.81%
Revenue NQ rev (3m)0.87%
Revenue NY rev (1m)1.48%
Revenue NY rev (3m)1.66%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 26.62 | ||
| Fwd PE | 25.04 | ||
| P/S | 13.23 | ||
| P/FCF | 26.33 | ||
| P/OCF | 25.7 | ||
| P/B | 7.5 | ||
| P/tB | 8.46 | ||
| EV/EBITDA | 25.53 |
EPS(TTM)1.64
EY3.76%
EPS(NY)1.74
Fwd EY3.99%
FCF(TTM)1.66
FCFY3.8%
OCF(TTM)1.7
OCFY3.89%
SpS3.3
BVpS5.82
TBVpS5.16
PEG (NY)1.9
PEG (5Y)0.34
Graham Number14.65
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 20.13% | ||
| ROE | 23.1% | ||
| ROCE | 22.1% | ||
| ROIC | 18.16% | ||
| ROICexc | 85.05% | ||
| ROICexgc | 177.37% | ||
| OM | 39.72% | ||
| PM (TTM) | 40.72% | ||
| GM | 90.2% | ||
| FCFM | 50.23% |
ROA(3y)13.75%
ROA(5y)12.65%
ROE(3y)16.22%
ROE(5y)15.68%
ROIC(3y)14.17%
ROIC(5y)16.48%
ROICexc(3y)82.49%
ROICexc(5y)193.92%
ROICexgc(3y)186.25%
ROICexgc(5y)N/A
ROCE(3y)17.25%
ROCE(5y)20.05%
ROICexgc growth 3Y3.35%
ROICexgc growth 5YN/A
ROICexc growth 3Y-4.75%
ROICexc growth 5YN/A
OM growth 3Y6.88%
OM growth 5Y16.16%
PM growth 3Y0.28%
PM growth 5Y33.35%
GM growth 3Y0.66%
GM growth 5Y0.68%
F-Score9
Asset Turnover0.49
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 64.81% | ||
| Cap/Sales | 1.23% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 123.66% | ||
| Profit Quality | 123.35% | ||
| Current Ratio | 7.79 | ||
| Quick Ratio | 7.79 | ||
| Altman-Z | 32.63 |
F-Score9
WACC9.37%
ROIC/WACC1.94
Cap/Depr(3y)59.31%
Cap/Depr(5y)83.25%
Cap/Sales(3y)1.28%
Cap/Sales(5y)1.55%
Profit Quality(3y)131.35%
Profit Quality(5y)169.54%
High Growth Momentum
Growth
EPS 1Y (TTM)46.43%
EPS 3Y20.79%
EPS 5Y79.21%
EPS Q2Q%50%
EPS Next Y14.02%
EPS Next 2Y11.19%
EPS Next 3Y11.61%
EPS Next 5Y14.75%
Revenue 1Y (TTM)20.21%
Revenue growth 3Y18.42%
Revenue growth 5Y37.42%
Sales Q2Q%23.16%
Revenue Next Year13.88%
Revenue Next 2Y12.44%
Revenue Next 3Y11.89%
Revenue Next 5Y11.49%
EBIT growth 1Y22.24%
EBIT growth 3Y26.56%
EBIT growth 5Y59.63%
EBIT Next Year17.62%
EBIT Next 3Y13.59%
EBIT Next 5Y14.23%
FCF growth 1Y94.7%
FCF growth 3Y30.18%
FCF growth 5Y64.72%
OCF growth 1Y93.3%
OCF growth 3Y29.24%
OCF growth 5Y59.83%
DOXIMITY INC-CLASS A / DOCS FAQ
What is the fundamental rating for DOCS stock?
ChartMill assigns a fundamental rating of 7 / 10 to DOCS.
Can you provide the valuation status for DOXIMITY INC-CLASS A?
ChartMill assigns a valuation rating of 4 / 10 to DOXIMITY INC-CLASS A (DOCS). This can be considered as Fairly Valued.
How profitable is DOXIMITY INC-CLASS A (DOCS) stock?
DOXIMITY INC-CLASS A (DOCS) has a profitability rating of 9 / 10.
What is the earnings growth outlook for DOXIMITY INC-CLASS A?
The Earnings per Share (EPS) of DOXIMITY INC-CLASS A (DOCS) is expected to grow by 14.02% in the next year.